Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNV2Y6
|
|||
| Drug Name |
TARA-002
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Lymphatic malformation [ICD-11: LA90.1] | Phase 2 | [1] | |
| Company |
Protara Therapeutics New York, NY
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05871970) A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.